Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CD34 Selection for GVHD Prophylaxis Using Automated CliniMACS
NCT06047886Phase 1Recruiting
- Sponsor
- University of Alabama at Birmingham
- Start
- Apr 2025
- Primary completion
- Oct 2029
- Modality
- Stem Cell Therapies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of CD34+ hematopoietic progenitor cells in graft-versus-host disease (GVHD) and Graft failure, sponsored by University of Alabama at Birmingham. Primary endpoints: Severe acute Graft Versus Host Disease at 6 years, Extensive chronic Graft Versus Host Disease at 6 years and 2 more. Started Apr 2025; status: recruiting.
02
Drugs
CD34+ hematopoietic progenitor cells
03
Conditions
graft-versus-host disease (GVHD)Graft failure
Beyond the preview
Go deeper on NCT06047886.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06047886.